drugset / Trial / NCT07390851

Magnesium Sulfate as an Adjuvant to Lidocaine in MPDS Trigger Point Injections Assessed by VAS and sEMG.

NCT07390851

Recruiting 28 enrolled Cairo University
RandomizedParallel-groupDouble-blindTreatment

Summary

Two groups of patients diagnosed with Myofascial Pain Dysfunction Syndrome (MPDS) will be included in this study. One group will receive trigger point injections of lidocaine alone. The other group will receive trigger point injections of lidocaine combined with magnesium sulfate. The study aims to compare the effectiveness of both treatments in reducing pain and improving muscle function. Patients will be assessed using a pain scale (VAS) and surface electromyography (sEMG) to measure muscle activity.

Timeline

Start
2025-11-26
Primary completion
2026-11-26
Completion
2026-11-26

Drugs

EvaluationDrugModalityDoseRoute
Comparator Lidocaine Other / unclassified 2 % Intramuscular
Subject Magnesium Sulfate Other / unclassified 10 % Intramuscular